VIP vs ACTH
Vasoactive intestinal peptide (VIP) and adrenocorticotropic hormone (ACTH) represent two fundamentally different classes of signaling molecules that share structural ancestry in the secretin-glucagon superfamily. VIP is a 28-amino acid neuropeptide with diverse physiological roles, while ACTH is a 39-amino acid hormone that regulates cortisol biosynthesis through adrenal cortex stimulation.
Molecular Identity
Section titled “Molecular Identity”- Sequence: His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH₂
- Molecular weight: ~3,326 Da
- Classification: Neuropeptide, secretin superfamily member
- Distribution: CNS neurons, enteric nervous system, immune cells, pancreatic islets
- Receptors: VPAC1 (widely expressed), VPAC2 (immune, endocrine), PACAP-preferring receptor
- Sequence: Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-Gly-Lys-Lys-Arg-Arg-Pro-Val-Lys-Val-Tyr-Pro-Asp-Gly-Ala-Glu-Asp-Glu-Leu-Ala-Glu-Ala-Phe-Pro-Leu-Glu-Phe
- Molecular weight: ~4,538 Da
- Classification: Polypeptide hormone, POMC-derived
- Origin: Anterior pituitary corticotrophs (cleaved from pro-opiomelanocortin)
- Receptor: MC2R (melanocortin 2 receptor) on adrenal cortex
Mechanism of Action
Section titled “Mechanism of Action”VIP: Versatile Signaling
Section titled “VIP: Versatile Signaling”VIP operates through multiple receptor-mediated pathways:
-
VPAC1 signaling: Gαs → cAMP ↑ → PKA activation → smooth muscle relaxation, chloride secretion, vasodilation
-
VPAC2 signaling: Gαs → cAMP ↑ → immune cell modulation, circadian rhythm regulation, insulin secretion
-
Enteric nervous system: VIP is the primary inhibitory neurotransmitter in the gut, mediating relaxation of smooth muscle and secretion of water/electrolytes.
-
Pulmonary function: VIP causes bronchodilation and pulmonary vasodilation, acting as a local regulator of airway tone.
-
Immune modulation: VIP suppresses pro-inflammatory cytokines (TNF-α, IL-6) and promotes anti-inflammatory mediators (IL-10).
-
Circadian regulation: VPAC2 in the suprachiasmatic nucleus mediates circadian phase shifts.
ACTH: Stress Axis Regulation
Section titled “ACTH: Stress Axis Regulation”ACTH operates through a focused adrenal cortex pathway:
-
MC2R binding: ACTH binds MC2R on zona fasciculata cells with high affinity.
-
cAMP-PKA signaling: Gαs → cAMP ↑ → PKA activation → cholesterol ester hydroxylase (CYP11A1) and 17α-hydroxylase (CYP17A1) phosphorylation.
-
Steroidogenesis: ACTH acutely stimulates cortisol synthesis by phosphorylating steroidogenic acute regulatory protein (StAR), facilitating cholesterol transport to mitochondria.
-
Adrenal maintenance: Chronic ACTH maintains adrenal cortex mass and function; absence leads to adrenal atrophy.
-
Melanocortin system: ACTH is a weak agonist at MC1R (skin pigmentation), which explains hyperpigmentation in Addison’s disease.
Comparison Table
Section titled “Comparison Table”| Property | VIP | ACTH |
|---|---|---|
| Sequence length | 28 amino acids | 39 amino acids |
| Molecular weight | ~3,326 Da | ~4,538 Da |
| Family | Secretin-glucagon | POMC-derived |
| Primary source | Neurons, enteric NS | Anterior pituitary |
| Primary target | Multiple (gut, lung, immune) | Adrenal cortex |
| Receptor(s) | VPAC1, VPAC2 | MC2R |
| Second messenger | cAMP | cAMP |
| Half-life | 1–2 minutes | 15–30 minutes |
| Plasma concentration | pg/mL range | pg/mL range |
Physiological Roles
Section titled “Physiological Roles”VIP Functions
Section titled “VIP Functions”| System | Function | Mechanism |
|---|---|---|
| Gastrointestinal | Smooth muscle relaxation, secretion | VPAC1 → cAMP |
| Pulmonary | Bronchodilation, vasodilation | VPAC1/VPAC2 → cAMP |
| Immune | Anti-inflammatory modulation | VPAC1/VPAC2 → cAMP |
| Endocrine | Insulin secretion, GH release | VPAC2 → cAMP |
| Neurological | Circadian regulation, neuroprotection | VPAC2 (SCN) |
| Cardiovascular | Vasodilation, hypotension | VPAC1 → cAMP |
ACTH Functions
Section titled “ACTH Functions”| System | Function | Mechanism |
|---|---|---|
| Adrenal cortex | Cortisol synthesis (acute) | MC2R → cAMP → StAR |
| Adrenal cortex | Cortisol synthesis (chronic) | MC2R → gene transcription |
| Adrenal maintenance | Trophic support | MC2R → growth signals |
| Skin pigmentation | Melanogenesis (weak) | MC1R (cross-reactivity) |
| CNS | Alertness, memory (via cortisol) | Indirect (cortisol effects) |
Clinical Applications
Section titled “Clinical Applications”| Indication | Mechanism | Evidence |
|---|---|---|
| Pulmonary arterial hypertension | Pulmonary vasodilation | Approved (Viprem) |
| Vasoactive intestinal peptide-producing tumor (VIPoma) | Diagnostic marker | Established |
| Sepsis/systemic inflammation | Anti-inflammatory | Phase II |
| Erectile dysfunction | Cavernosal smooth muscle relaxation | Phase II |
| Functional GI disorders | Enteric neuromodulation | Investigational |
| Indication | Mechanism | Evidence |
|---|---|---|
| Infantile spasms (West syndrome) | Unclear (cortisol + direct CNS) | First-line therapy |
| Adrenal insufficiency diagnosis | Cortisol stimulation | Standard diagnostic test |
| Anti-inflammatory (historical) | Cortisol-mediated | Largely replaced by synthetic glucocorticoids |
| Multiple sclerosis (historical) | Immunosuppression | Historical use |
| Nephrotic syndrome (adjunct) | Immunosuppression | Limited use |
Pharmacokinetics
Section titled “Pharmacokinetics”| Parameter | VIP | ACTH |
|---|---|---|
| Half-life | 1–2 min | 15–30 min |
| Hepatic extraction | ~60% | ~30% |
| Renal clearance | ~40% | ~50% |
| IV infusion required | Yes (continuous) | Yes (for stimulation test) |
| Oral bioavailability | Negligible | Negligible |
| Nasal absorption | Limited | Limited |
Both peptides have short half-lives, necessitating parenteral administration for therapeutic use. VIP’s 1–2 minute half-life makes it particularly challenging to administer, requiring continuous IV infusion.
Pathological States
Section titled “Pathological States”VIP Deficiency/Dysfunction
Section titled “VIP Deficiency/Dysfunction”| Condition | Mechanism |
|---|---|
| Verner-Morrison syndrome (VIPoma) | Excess VIP → secretory diarrhea |
| Achalasia | Loss of VIP neurons in esophageal myenteric plexus |
| Irritable bowel syndrome | Altered VIP signaling |
| Pulmonary hypertension | Reduced VIP-mediated vasodilation |
ACTH Excess/Deficiency
Section titled “ACTH Excess/Deficiency”| Condition | Mechanism |
|---|---|
| Cushing’s disease | Excess ACTH → cortisol excess |
| Addison’s disease | ACTH excess (compensatory) + cortisol deficiency |
| Secondary adrenal insufficiency | ACTH deficiency → cortisol deficiency |
| Ectopic ACTH syndrome | Non-pituitary ACTH production → Cushing’s |
Safety Profile
Section titled “Safety Profile”| Parameter | VIP | ACTH |
|---|---|---|
| Hypotension | Common (dose-limiting) | Rare |
| Flushing | Common | Rare |
| Diarrhea | Common (GI stimulation) | Rare |
| Hyperpigmentation | None | At high doses (MC1R cross-reactivity) |
| Adrenal suppression | None | With chronic use (HPA axis) |
| Allergic reaction | Rare | Rare |
Key Takeaways
Section titled “Key Takeaways”VIP and ACTH represent the divergent evolution of the secretin-glucagon superfamily into specialized signaling molecules. VIP diversified into a versatile neuropeptide with roles in GI motility, pulmonary function, immune modulation, and circadian regulation, operating through multiple receptor subtypes. ACTH specialized into a focused stress hormone that regulates cortisol biosynthesis through a single receptor (MC2R). Their structural ancestry belies their functional divergence — VIP serves as a local neurotransmitter with systemic effects, while ACTH functions as a systemic hormone with localized adrenal action.